Table II.
| WHO 2010 classification, n (%) | |||||
|---|---|---|---|---|---|
|
|
|||||
| GEP-NET | WHO 2000 classification, n (%)b | No datac | NET G1 | NET G2 | NEC G3 |
| WDET | 92 (20.1) | 28 (30.4) | 51 (55.5) | 13 (14.1) | 0 (0.0) |
| WDEC | 304 (66.5) | 72 (23.7) | 82 (27.0) | 144 (47.4) | 6 (1.9) |
| PDEC | 47 (10.3) | 11 (23.4) | 0 (0.0) | 4 (8.5) | 32 (68.1) |
| Others | 14 (3.1) | 6 (42.9) | 2 (14.3) | 3 (21.4) | 3 (21.4) |
| Total | 457 (100.0) | 117 (25.6) | 135 (29.5) | 164 (35.9) | 41 (9.0) |
a
The table is based on 457 patients for whom data were available.
b
The percentages in the second column are percentages of the total number of classified patients.
c
In the ‘No data’ columns, G1, G2 and G3 are percentages of each line of NET and NEC, differentiated neuroendocrine tumor (NET) G1, G2 and neuroendocrine carcinoma (NEC) G3.
WHO, World Health Organization; GEP, gastroenteropancreatic; NET, neuroendocrine tumor; G1, grade 1; G2, grade 2; G3, grade 3; WDET, well-differentiated NET; WDEC, well-differentiated NEC; PDEC, poorly differentiated NEC.